This review summarizes the efficacy and drawbacks of current anti-arrhythmic agents and thromboembolism prophylaxis for the management of atrial fibrillation.
Answers are grounded in this paper and cite their sources.
May inform AF drug selection amid toxicity concerns; leaves open needs for safer agents in future trials.
Atrial fibrillation (AF) remains a widespread health problem and the drugs available for its treatment suffer from several drawbacks, including potentially lethal proarrhythmia, serious non-cardiac toxicity and limited efficacy. The evidence for efficacy of currently available anti-arrhythmic agents for sinus rhythm restoration and maintenance is reviewed, with emphasis on randomised trials when available. The current approach to thromboembolism prophylaxis in AF is summarised.
No takes yet. Share an insight, caveat, or question.
Němec et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: